Sanofi Raises Full-Year Guidance After Strong Third-Quarter Results
J.P. Morgan analysts say Sanofi reported strong third-quarter results and raised its full-year guidance. The body is truncated after mentioning Dupixent.
Sanofi reported strong results for the third quarter and raised its full-year guidance, which should be well received by investors, J.P. Morgan analysts say in a research note. The French drugmaker's blockbuster drug Dupixent--developed jointly with Regeneron Pharmaceuticals--accounted for around h…